Cell Cryopreservation Market: Market Size & Forecast 2026

The cell cryopreservation market covers the technologies that preserve cells, including cryoprotectants, freezing media, controlled-rate freezers, liquid-nitrogen storage tanks, automated cryogenic systems, and associated biobanking services. Demand spans pharmaceutical and biotechnology companies, hospitals and academic medical centers, stem cell and cord blood banks, and research laboratories. Consistent estimates place the market near $14.4 billion in 2025, with a projected annual growth rate in the high teens to low twenties percent through the next decade.

• •Market size in 2025 is approximately $14.4 billion, based on a consensus of multiple private research estimates.
• •No official government statistical agency publishes a standardized size figure for this market, contributing to wide variation across reports.

The strongest growth tailwind comes from the rapid clinical and commercial expansion of cell and gene therapies, which require reliable long-term preservation of autologous and allogeneic cell products. Growth is reinforced by the steady expansion of public and private biobanks, increased newborn cord blood and tissue banking, and rising R&D investment in regenerative medicine and personalized oncology therapeutics. Improvements in cryoprotectant chemistry, automated storage platforms, and cold-chain logistics are also enabling more reproducible, large-scale preservation than was previously possible.

• •Expanding pipelines of cell and gene therapies create sustained demand for high-quality cryopreserved cell products.
• •Public and private biobanks, including cord blood and tissue banks, continue to grow in volume and geographic reach.
• •Improvements in cryoprotectants, controlled-rate freezing, and automated storage are improving post-thaw viability and scalability.

The market is commonly segmented by product (consumables such as cryoprotectants and freezing media; equipment such as freezers and storage tanks; and software and services including biobanking), by cell type (stem cells, cord blood cells, immune cells, oocytes and sperm, and other primary cells), and by end-user (pharma and biotech, hospitals, research institutes, and biobanks). North America holds the largest share, supported by an advanced regenerative medicine sector, established biobanking infrastructure, and the presence of major therapy developers, while Europe remains a mature second market and Asia-Pacific is the fastest-growing region on the back of rising healthcare investment, expanding stem cell banking, and growing clinical trial activity in China, Japan, South Korea, and India.

• •North America holds the largest share due to strong cell and gene therapy R&D and established biobanking networks.
• •Asia-Pacific is the fastest-growing region, supported by expanding healthcare investment and stem cell banking activity.

What are the recent trends and outlook?

Looking ahead, the market is expected to continue growing at a high-teens to low-twenties annual percentage through the end of the decade as cell and gene therapies move deeper into commercial use and biobanking scale increases. Key trends include wider adoption of closed-system, automated cryopreservation to reduce handling variability for cell therapies, integration of digital inventory management and chain-of-custody software with physical cold storage, and the build-out of GMP-compliant, decentralized cryogenic logistics networks. Longer term, improvements in vitrification methods, DMSO-free cryoprotectants, and AI-supported storage monitoring are likely to expand applications into reproductive medicine, organoid banking, and large-scale allogeneic cell manufacturing.

• •Automation, closed-system processing, and digital inventory software are increasingly standard in cell therapy manufacturing.
• •DMSO-free cryoprotectants, improved vitrification, and AI-based storage monitoring are emerging R&D directions.